Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
Go back to Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies| (AMEX: MKKGY) | Delayed: 33.29 -0.26 (0.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.55 | 52 Week High | $ | |||
| Open | $32.68 | 52 Week Low | $ | |||
| Day High | $33.48 | P/E | N/A | |||
| Day Low | $32.68 | EPS | $ | |||
| Volume | 168,623 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 128.66 +3.21 (2.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $125.45 | 52 Week High | $65.46 | |||
| Open | $125.83 | 52 Week Low | $47.97 | |||
| Day High | $128.78 | P/E | 87.52 | |||
| Day Low | $125.83 | EPS | $1.47 | |||
| Volume | 18,891,511 | |||||
